AIMP1 and glioblastoma: Through the survival analysis of four cohorts, we showed inconsistent effects of the AIMPs on survival in heterogeneous treatment groups, indicating that the potential prognostic impact of AIMP1/2/3 is potentially treatment dependent, and through retrospective analysis of two recurrent GBM antiangiogenic clinical trials, we established the role of AIMP2 as a predictive molecular biomarker for antiangiogenic treatment response.